Azacitidine
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-AZACITIDINE |
|---|---|
| Type | Drug |
| Aliases | Onureg (oral)VidazaАзацитидин |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-AITL DIS-AML DIS-MDS-HR |
| Sources | SRC-ESMO-MDS-2021 SRC-NCCN-AML-2025 SRC-VIALE-A-DINARDO-2020 |
Drug Facts
| Class | Hypomethylating agent (cytidine analog) |
|---|---|
| Mechanism | Pyrimidine nucleoside analog incorporated into DNA and RNA, inhibits DNA methyltransferases → re-expression of silenced tumor-suppressor genes + cytotoxicity at higher doses. Backbone of MDS-HR, AML-unfit (with venetoclax), and CMML 1L therapy. |
| Typical dosing | SC/IV 75 mg/m²/day × 7 days every 28-day cycle (most common); 5-2-2 schedule (5 d on, 2 d off, 2 d on) acceptable. Continue ≥6 cycles before declaring failure (response often delayed 4-6 cycles). Ven+aza for AML: azacitidine 75 mg/m² days 1-7 + venetoclax ramp. |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
Used in MDS-HR (1L), AML-unfit (with venetoclax — VIALE-A), CMML, and AML maintenance (oral Onureg post-induction in selected patients). Response delayed — do NOT discontinue before cycle 6 unless overt progression. SC equivalent to IV; SC preferred outpatient.
Used By
Regimens
REG-ALLOHCT-MDS-HR- Allogeneic hematopoietic cell transplant for high-risk MDSREG-AZA-MDS-HR- Azacitidine (MDS-HR 1L)REG-AZACITIDINE-AITL- 5-Azacitidine SC/IV 75 mg/m² days 1-7 q28d — r/r AITL (epigenetic-targeted)REG-ORAL-AZA-QUAZAR-MAINTENANCE- Oral azacitidine (CC-486 / Onureg) maintenance — AML CR1, transplant-ineligible (QUAZAR A...REG-VEN-AZA-AML- Venetoclax + Azacitidine (AML, unfit) — VIALE-A schedule